Lessons from genetically engineered animal models X. Trefoil peptide and EGF receptor/ligand transgenic mice

American Journal of Physiology

Volumn 278, Issue 4 PART 1, 2000, Pages

  Giraud, Andrew S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Epidermal growth factor receptor; Transforming growth factor ; Transgenic mice

Indexed keywords

EID: 0033995520     PISSN: 00029513     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Alison MR, Chinery R, Poulsom R, Ashwood P, Loncroft JM, and Wright NA. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor-α mRNAs in rat stomach. J Pathol 175: 405-414, 1995.
2. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, and Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 108: 564-580, 1995.
3. Beck PL and Podolsky DK. Intestinal trefoil factor reduces the severity of chemotherapy and radiotherapy-induced intestinal mucositis (Abstract). Gastroenterology 116: G2133, 1999.
4. Bookman DE and Merlino G. Cytological changes in the pancreas of transgenic mice overexpressing transforming growth factor α. Gastroenterology 103: 1883-1892.
5. Calnan DP, Westley BR, May REB, Floyd DN, Marchbank T, and Playford RJ. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 188: 312-317, 1999.
6. Chinery R and Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Colch) 88: 401-403, 1995.
7. Cook GA, Familari M, Thim L, and Giraud AS. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett 456: 155-159, 1999.
8. Cook GA, Yeomans ND, and Giraud AS. Temporal expression of trefoil peptides in the TGF-α knockout mouse after gastric ulceration. Am J Physiol Gastrointest Liver Physiol 272: G1540-G1549, 1997.
9. Dempsey PJ, Goldenring JR, Soroka CJ, Modlin IM, McClure RW, Lind CD, Alquist DA, Pittelkow MR, Lee DC, Sandgren EP, Page DL, and Coffey RJ. Possible role of transforming growth factor TGF-α in the pathogenesis of Menetrier's disease: supportive evidence in humans and transgenic mice. Gastroenterology 103: 1950-1963, 1992.
10. Dignass A, Lynch-Devaney K, Kindon H, Thim L, and Podolsky DK. Trefoil peptides promote epithelial migration through a transforming growth factor-α-independent pathway. J Clin Invest 94: 376-383, 1994.
11. Dunn AR, Mann GB, Fowler KJ, Grail D, Hibbs ML, Alexander WS, Walker F, and Burgess AW. Insights into the physiology of TGF α and signalling through the EGF receptor revealed by gene targeting and acts of nature. Princess Takamatsu Symp 24: 276-89, 1994.
12. Egger B, Procaccino F, Lakshmanan J, Reinshagen M, Hoffmann P, Patel A, Reuben W, Gnanakkan S, Liu L, Barajas L, and Eysselein VE. Mice lacking transforming growth factor α have an increased susceptibility to dextransulfate-induced colitis. Gastroenterology 113: 825-832, 1997.
13. Egger B, Carey HV, Procaccino F, Chai NN, Sandgren EP, Lakshmanan J, Buslon VS, French SW, Buchler MW, and Eysselein VE. Reduced susceptibility of mice overexpressing transforming growth factor α to dextran sodium sulfate induced colitis. Gut 43: 64-70, 1998.
14. Fausto N. Lessons From Genetically Engineered Animal Models. V. Knocking out genes to study liver regeneration: present and future. Am J Physiol Gastrointest Liver Physiol 277: G917-G921, 1999.
15. Goldenring JR, Poulsom R, Ray GS, Wright N, Meise KS, and Coffey RJ. Expression of trefoil peptides in the gastric mucosa of transgenic mice overexpressing transforming growth factor-α. Growth Factors 13: 111-119, 1996.
16. Karam SM and Leblond CP. Dynamics of epithelial cells in the corpus of the mouse stomach. III. Inward migration of neck cells followed by progressive transformation into zymogenic cells. Anat Rec 236: 297-313, 1993.
17. Lefebvre O, Chenard M-P, Masson R, Linares J, Dierich A, Lemeur M, Wendung C, Tomasetto C, Chambon P, and Rio M-C. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 protein. Science 274: 259-262, 1996.
18. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, and Lee DC. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750, 1999.
19. Marchbank T, Cox H, Goodlad R, Giraud AS, Moss S, Wright NA, and Playford RJ. Transgenic mice overexpressing TFF3 (rat intestinal trefoil factor) within the jejunum have an increased regional resistance to intestinal damage, but no difference in cell migration or apoptosis (Abstract). Gastroenterology 116: G4000, 1999.
20. Mashimo H, Wu D-C, Podolsky DK, and Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274: 262-265, 1996.
21. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pederson RA, Werb Z, and Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376: 337-341, 1995.
22. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM, and Wright NA. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 93: 2137-2142, 1996.
23. Sandgren EP, Luetteke NC, Qui TH, Palmiter RD, Brewster RL, and Lee DC. Transforming growth factor α dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol Cell Biol 13: 320-330, 1993.
24. Sharp R, Babyatsky MW, Takagi H, Tagerud S, Wang TC, Bookman DE, Brand SJ, and Merlino G. Transforming growth factor α disrupts the normal program of cellular differentiation program hi the gastric mucosa of transgenic mice. Development 121: 149-161, 1995.
25. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, and Folkman J. Betacellulin: a mitogen from pancreatic β cell tumors. Science 259: 1604-1607, 1993.
26. Sibilia M and Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269: 234-238, 1995.
27. Taupin DR, Kinoshita K, and Podolsky DK. The trefoil peptide ITF regulates colonic epithelial apoptosis and tumor cell resistance to chemotherapy (Abstract). Gastroenterology 116: G2269, 1999.
28. Taupin D, Wu D-C, Jeon W-K, Devaney K, Wang TC, and Podolsky DK. The trefoil peptide gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interrelation. J Clin Invest 103: R31-R38, 1999.
29. Thim L. Trefoil peptides: a new family of gastrointestinal molecules. Digestion 55: 353-360, 1994.
30. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RJ, and Magnuson T. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269: 230-234, 1995.
31. Toyoda H, Komurasaki T, Uchida D, and Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 326: 69-75, 1997.
32. Tran CP, Cook GA, Yeomans ND, Thim L, and Giraud AS. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44: 636-642, 1999.
33. Vaughan TJ, Pascall JC, and Brown KD. Tissue distribution of mRNA for heparin-binding epidermal growth factor. Biochem J 287: 681-684, 1992.
34. Wagner M, Luhrs H, Kloppel G, Adler G, and Schmid RM. Malignant transformation of duct-like cells originating from acini in transforming growth factor α transgenic mice. Gastroenterology 115: 1254-1262, 1998.
35. b-tsA58 transgenic mice. Proc Natl Acad Sci USA 90: 587-591, 1993.
36. Wright NA, Pike C, and Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in gastrointestinal stem cells. Nature 343: 82-85, 1990.